Fig. 7.
GSK-650394, but not 14-3-3β small-interfering RNA (siRNA), prevented neuropathic injury–induced phosphorylated serum- and glucocorticoid-inducible kinase 1 (pSGK1)-phosphorylated histone deacetylase (pHDAC4) colocalization. (A) Immunohistochemical images showing spinal nerve ligation (SNL) notably enhanced the immunoreactivity of pSGK1 (IV, green) and pHDAC4 (V, red) compared with the sham group (Sham, I and II, respectively) in the ipsilateral dorsal horn of spinal slices obtained at day 7 after operation (7D). Overlay images and the count of double-labeled neurons show SNL enhanced the colocalized immunoreactivity of pSGK1 with pHDAC4 in the dorsal horn (VI and VIa, yellow), which were remarkably reduced by the administration with GSK-650394 (an SGK1 inhibitor; 30 nM, 10 μl; SNL7D + GSK, IX and IXa), but not 14-3-3β messenger RNA-targeting small interfering RNA (SNL 7D + 14-3-3β RNAi, XII and XIIa). (B) Statistical analysis showing SNL notably enhanced the count of pSGK1-positive, pHDAC4-positive, and double-labeled dorsal horn that were remarkably reduced by the administration with GSK-650394 (SNL7D + GSK), but not 14-3-3β mRNA-targeting siRNA (SNL 7D + 14-3-3β RNAi, ** P < 0.01 compared with the Sham 7D, ##P < 0.01 compared with the SNL 7D, n = 7).